Latest news with #DavidLlewellyn
Yahoo
5 days ago
- Business
- Yahoo
Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells
BEACHWOOD, Ohio, Aug. 5, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company advancing scalable human cell models derived from induced pluripotent stem cells (iPSCs), announces the commercial release of TrailBio® Hematopoietic Progenitor Cells. These progenitor cells are derived from a single, well-characterized iPSC line using Trailhead's proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, providing researchers with a consistent, scalable, and ready-to-use tool for hematopoietic research. TrailBio® Hematopoietic Progenitor Cells express key hematopoietic markers including CD34, CD43 and CD90. Functional characterization confirms their ability to form myeloid and erythroid colonies in colony-forming unit (CFU) assays, differentiate into multiple hematopoietic lineages and demonstrate hematopoietic commitment through transcriptomic profiling. Designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio® Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports reproducible results. "TrailBio® Hematopoietic Progenitor Cells strengthen our portfolio by providing researchers with high-quality, human-relevant cellular models," said David Llewellyn, Chief Executive Officer of Trailhead Biosystems. "Their consistency and multipotency enable scientists to advance research in hematopoietic biology and therapeutic development." "These Hematopoietic Progenitor Cells deliver a dependable combination of purity, potency and versatility," said Angelica Gomes Ueltschy, Scientific Director at Trailhead Biosystems. "Their robust marker expression and multilineage differentiation capacity make them well suited for modeling blood disorders and evaluating therapeutic candidates." Cell characterization information and additional data can be found at About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® Hematopoietic Progenitor Cells join a growing portfolio of iPSC-derived human cell types designed to bridge the gap between discovery and clinical translation. Learn more about Trailhead Biosystems, TrailBio® Hematopoietic Progenitor Cells and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
5 days ago
- Business
- Cision Canada
Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells
BEACHWOOD, Ohio, Aug. 5, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company advancing scalable human cell models derived from induced pluripotent stem cells (iPSCs), announces the commercial release of TrailBio ® Hematopoietic Progenitor Cells. These progenitor cells are derived from a single, well-characterized iPSC line using Trailhead's proprietary High-Dimensional Design-of-Experiments (HD-DoE ®) platform, providing researchers with a consistent, scalable, and ready-to-use tool for hematopoietic research. TrailBio ® Hematopoietic Progenitor Cells express key hematopoietic markers including CD34, CD43 and CD90. Functional characterization confirms their ability to form myeloid and erythroid colonies in colony-forming unit (CFU) assays, differentiate into multiple hematopoietic lineages and demonstrate hematopoietic commitment through transcriptomic profiling. Designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio ® Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports reproducible results. "TrailBio ® Hematopoietic Progenitor Cells strengthen our portfolio by providing researchers with high-quality, human-relevant cellular models," said David Llewellyn, Chief Executive Officer of Trailhead Biosystems. "Their consistency and multipotency enable scientists to advance research in hematopoietic biology and therapeutic development." "These Hematopoietic Progenitor Cells deliver a dependable combination of purity, potency and versatility," said Angelica Gomes Ueltschy, Scientific Director at Trailhead Biosystems. "Their robust marker expression and multilineage differentiation capacity make them well suited for modeling blood disorders and evaluating therapeutic candidates." Cell characterization information and additional data can be found at About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE ®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio ® Hematopoietic Progenitor Cells join a growing portfolio of iPSC-derived human cell types designed to bridge the gap between discovery and clinical translation. Learn more about Trailhead Biosystems, TrailBio® Hematopoietic Progenitor Cells and HD-DoE® at For more information, please contact: Tim Mauk, Corporate Communications Trailhead Biosystems Email: [email protected] SOURCE Trailhead Biosystems Inc
Yahoo
5 days ago
- Business
- Yahoo
Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells
BEACHWOOD, Ohio, Aug. 5, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company advancing scalable human cell models derived from induced pluripotent stem cells (iPSCs), announces the commercial release of TrailBio® Hematopoietic Progenitor Cells. These progenitor cells are derived from a single, well-characterized iPSC line using Trailhead's proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, providing researchers with a consistent, scalable, and ready-to-use tool for hematopoietic research. TrailBio® Hematopoietic Progenitor Cells express key hematopoietic markers including CD34, CD43 and CD90. Functional characterization confirms their ability to form myeloid and erythroid colonies in colony-forming unit (CFU) assays, differentiate into multiple hematopoietic lineages and demonstrate hematopoietic commitment through transcriptomic profiling. Designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio® Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports reproducible results. "TrailBio® Hematopoietic Progenitor Cells strengthen our portfolio by providing researchers with high-quality, human-relevant cellular models," said David Llewellyn, Chief Executive Officer of Trailhead Biosystems. "Their consistency and multipotency enable scientists to advance research in hematopoietic biology and therapeutic development." "These Hematopoietic Progenitor Cells deliver a dependable combination of purity, potency and versatility," said Angelica Gomes Ueltschy, Scientific Director at Trailhead Biosystems. "Their robust marker expression and multilineage differentiation capacity make them well suited for modeling blood disorders and evaluating therapeutic candidates." Cell characterization information and additional data can be found at About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® Hematopoietic Progenitor Cells join a growing portfolio of iPSC-derived human cell types designed to bridge the gap between discovery and clinical translation. Learn more about Trailhead Biosystems, TrailBio® Hematopoietic Progenitor Cells and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
South Wales Argus
11-07-2025
- Health
- South Wales Argus
Newport is first Welsh city to prescribe nature as medicine
Newport has become the first city in Wales to launch RSPB Nature Prescriptions, a non-medical approach to health that encourages people to connect with the natural world through simple, self-led activities. The scheme is delivered in partnership with the Aneurin Bevan University Health Board. David Llewellyn, nature and wellbeing manager at RSPB Cymru, said: "There is strong evidence which shows that spending time in nature reduces stress and anxiety while lowering blood pressure and boosting immunity through increased physical activity." The project is funded through the People's Postcode Lottery and builds on similar schemes already running in Scotland and England. Nature prescriptions can be offered by a range of trained professionals. These include GPs, social prescribers, occupational therapists, and community stroke support teams. Jonny Currie, a GP at Ringland Medical Practice, said: "As a GP in Newport, I know we need new ways to enable people to support their own wellbeing and health. "We know that connecting with nature can play a crucial role in doing this. "The RSPB Nature Prescriptions offer a great opportunity to help in doing that and we look forward to using them in our practice." Public support for the scheme appears strong. A recent survey by Beaufort Research found that 80 per cent of people believe spending time in nature is important for their health and wellbeing. Victoria Dyer, service development lead for the Integrated Wellbeing Network at Aneurin Bevan University Health Board, said: "This project is a perfect example of partnership working, with the contributions from our talented community playing a vital role in the imagery for this nature prescription. "We thank the RSPB for the opportunity and feel very proud to bring this resource to Newport and hope that many people will benefit from it." The RSPB hopes that the scheme will not only improve wellbeing but also foster a lasting appreciation of nature and a desire to protect it. More information about RSPB Nature Prescriptions is available on the RSPB website.
Wales Online
16-06-2025
- Wales Online
Man, 39, cupped teenage women's bottoms and whispered sexual comments in their ears
Man, 39, cupped teenage women's bottoms and whispered sexual comments in their ears After assaulting one of his victims, paedophile David Llewellyn said: "Come on, you love it." David Llewellyn, 39, sexually assaulted two teenage women by touching them on their bottoms. (Image: South Wales Police ) A man who had previously been found with indecent images of children sexually assaulted two teenage women by touching them on their bottoms. One of the victims said she had suffered sleepless nights as a result of the assault and was scared to go out at night. Paedophile David Llewellyn, 39, made sexualised comments towards his victims before he assaulted them and would whisper in their ears. This made the victims feel uncomfortable and anxious of being in the defendant's presence. A sentencing hearing at Cardiff Crown Court on Tuesday heard one of the victim's told Llewellyn she was just 19-years-old, to which he responded: "I've done much younger than that." For the latest court reports sign up to our crime newsletter. The first victim described how the defendant got "right in her face" and cornered her when she attempted to back away from him. Llewellyn later "cupped" the victim's bottom and smirked as he told her "Come on, you love it". The second victim said the defendant also touched her bottom. Article continues below When she turned round and accused him of sexually assaulting her, he replied: "Yes, I know." The court heard the victim felt "uncomfortable and vulnerable" following the assault. Llewellyn, of Tyndall Street, Butetown, Cardiff, denied two counts of sexual assault but was found guilty of both charges following a trial. The defendant has four previous convictions, including an offence of making indecent images in 2018. As a result of this conviction, Llewellyn was made subject to a Sexual Harm Prevention Order, which he has breached on a number of occasions. In a victim personal statement read to the court by prosecutor Thomas Stanway, one of the victims said suffered from "sleepless nights" and was "scared to go out at night". In mitigation, Paul Hewitt said his client's situation is "bleak" and "all he has going for him" is his supported accommodation, which he would lose if sent to prison. The defence barrister said the defendant suffers with anxiety, for which he has been prescribed medication. Sentencing, Judge Carl Harrison said the offences were too serious to be dealt with by anything other than an immediate custodial sentence. Article continues below He also said the defendant had "minimised" his actions when he was interviewed by the probation service. Llewellyn was sentenced to six months imprisonment.
